Eli Lil­ly tasks Nim­bus with hit­ting a 'high-val­ue' tar­get for di­a­betes, obe­si­ty

The com­pu­ta­tion­al chem­istry ex­perts at Nim­bus have al­ways tak­en pride in se­lect­ing com­pelling tar­gets and de­ploy­ing a struc­ture-based ap­proach to drug them. Eli Lil­ly is …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER